Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
about
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.Human epidermal growth factor receptor 2 and estrogen receptor status in respect to tumor characteristics in non-metastatic breast cancerPredicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think TankImmunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women.Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.Bone metastasis risk factors in breast cancer.Biomarkers of drugs targeting HER-family signalling in cancer.MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study.De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.Personalization of loco-regional care for primary breast cancer patients (part 1).Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy.
P2860
Q33757796-960E9456-FBD5-4CF6-8F8F-20913F6E7792Q33855396-5BA4E546-F6C1-412B-A2E9-C7D4B6C46D86Q34126938-59D4288B-1C59-4B25-ABCD-2623CFFB396EQ35159916-5107F871-6E28-4B48-98DB-2519F329102EQ36287896-0561639B-B777-408A-8EE0-432C511D726AQ36729467-AF0EE9FE-6566-43F3-B21A-32471CF4BF55Q36983960-2E74C0D2-2DD1-4ADF-9203-96C2EA442A47Q37094017-BB57BDC0-D4F7-4FD0-A62D-DFF5D7D0A470Q37247163-D5D4B76D-9CF8-4754-BBB3-78E6F344560AQ37629662-FA6C1456-516C-45CF-9C91-38147B28A75EQ38150774-E8D95089-A349-4C60-896C-D686326AC005Q38409734-08069B8B-E875-46F6-87C3-04D7EE3A8DD0Q39421814-B81586A6-9021-45E1-9CCF-4924ADFAB9B6Q41134799-7CBBE974-3130-417E-B313-1DAEDCD607F8Q41189272-9719DE08-3DCF-4571-8328-3CCB704AAA33Q44541840-2FA47B22-CC81-4CEF-8AA4-F591FD8BB513Q47727855-9B0861E8-2B3C-48A4-BFE4-BA74234B1322Q48489316-256CF082-2E99-46AC-B5AC-2FE03EF7E6D8Q53291372-67DA1A85-B60A-4F3E-AA78-912812A8634F
P2860
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Human epidermal growth factor ...... define two distinct subtypes?
@ast
Human epidermal growth factor ...... define two distinct subtypes?
@en
type
label
Human epidermal growth factor ...... define two distinct subtypes?
@ast
Human epidermal growth factor ...... define two distinct subtypes?
@en
prefLabel
Human epidermal growth factor ...... define two distinct subtypes?
@ast
Human epidermal growth factor ...... define two distinct subtypes?
@en
P2093
P2860
P356
P1433
P1476
Human epidermal growth factor ...... define two distinct subtypes?
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDS286
P577
2012-09-28T00:00:00Z